# Clinical Trials Data EGFR - Document 120

# A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

## Clinical Trial: https://clinicaltrials.gov/study/NCT01131429

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Male and female patients aged over 18 years\n\* Histologically proven lung adenocarcinoma\n\* clinical stage IIIB/IV\n\* ECOG performance status 0-2\n\* Had no prior anticancer agent, radiation or surgical therapy for lung adenocarcinoma\n\* At least one measurable lesion (according to RECIST)\n\* Provision of written informed consent\n\* Life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n\* History of malignant disease.\n\* Evidence of clinically active interstitial lung diseases (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded)\n\* Expected life expectancy less than 2 months\n\* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)\n\* Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) \u2265 2.5 x ULN if no demonstrable liver metastases (or \\>5 x in presence of liver metastases)\n\* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study\n\* Pregnancy or breast-feeding women (women of child\u00acbearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The eligibility criteria provided for the clinical trial do not mention any specific exclusions or requirements regarding EGFR gene mutations. Therefore, based solely on the information given, a patient with an EGFR gene mutation would not be automatically excluded from participating in the trial. However, it's important to confirm the eligibility criteria on a case-by-case basis with the trial investigators as there might be additional unpublished details or specific objectives of the study that pertain to genetic factors like EGFR mutations.